Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody

Bone Marrow Transplantation

Volumn 28, Issue 1, 2001, Pages 47-49

  Kobbe, G ^a   Schneider, P ^a   Rohr, U ^a   Fenk, R ^a   Neumann, F ^a   Aivado, M ^a   Dietze, L ^a   Kronenwett, R ^a   Hunerliturkoglu A ^a   Haas, R ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Graft versus host disease; Infliximab; TNF

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B LIPID COMPLEX; BUSULFAN; CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GANCICLOVIR; INFLIXIMAB; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; STEROID; THIOTEPA; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOMEGALOVIRUS; DEATH; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DONOR; DOSE RESPONSE; DRUG INFUSION; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LIVER DISEASE; LUNG MYCOSIS; LYMPHOCYTE TRANSFUSION; MALE; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; SKIN DISEASE; STEM CELL TRANSPLANTATION; VIRUS INFECTION; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MICE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; SALVAGE THERAPY; STEROIDS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034904530     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703094     Document Type: Article

References (8)

1. Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells
2. A retrospective analysis of therapy for acute graft-versus-host-disease: Secondary treatment
3. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
4. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease
5. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
6. Infliximab for the treatment of fistulas in patients with Crohn's disease
7. A cost-effectiveness analysis of treatment options for patients with methotrexate resistant rheumatoid arthritis
8. Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients